Literature DB >> 8031011

An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover.

R Hirschhorn1, D R Yang, A Israni.   

Abstract

We have now determined the molecular genetic basis for the common biochemical polymorphism at the adenosine deaminase (ADA) locus. The ADA*2 allele contains a G to A transition at nt22 (relative to the ATG) that results in substitution of asparagine for aspartic acid at codon 8 (Asp8Asn). Introduction of the nucleotide substitution into an ADA 1 cDNA and transfection into monkey kidney (Cos) cells confirmed that the mutation resulted in expression of an enzyme that comigrated with the naturally occurring ADA 2 allozyme. The substitution of neutral asparagine for anionic aspartic acid is consistent with the more cathodal electrophoretic migration of ADA 2 as compared with ADA 1. The nucleotide substitution was found on at least two different genetic backgrounds, suggesting independent recurrence of the mutation. Consistent with independent recurrence, the G to A transition is at a CpG dinucleotide and represents a type of mutation that occurs with high frequency. We have also unexpectedly identified a probable intragenic crossover in the very large first intron that is rich in repetitive DNA sequences.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031011

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  9 in total

Review 1.  Alpha-1 antitrypsin deficiency.

Authors:  R A Primhak; M S Tanner
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

2.  A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans.

Authors:  J V Rétey; M Adam; E Honegger; R Khatami; U F O Luhmann; H H Jung; W Berger; H-P Landolt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-12       Impact factor: 11.205

Review 3.  Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?

Authors:  Benjamin Hall; Jonathan G George; Scott P Allen
Journal:  Histol Histopathol       Date:  2021-12-09       Impact factor: 2.303

4.  Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.

Authors:  R Hirschhorn; D R Yang; A Israni; M L Huie; D R Ownby
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

5.  The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders.

Authors:  Joe A Hettinger; Xudong Liu; Jeanette Jeltje Anne Holden
Journal:  J Autism Dev Disord       Date:  2007-03-06

6.  Enzyme activities controlling adenosine levels in normal and neoplastic tissues.

Authors:  D Vannoni; A Bernini; F Carlucci; S Civitelli; M C Di Pietro; R Leoncini; F Rosi; A Tabucchi; G Tanzini; E Marinello
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  The ADA*2 allele of the adenosine deaminase gene (20q13.11) and recurrent spontaneous abortions: an age-dependent association.

Authors:  Daniela Prudente Teixeira Nunes; Lígia Cosentino Junqueira Franco Spegiorin; Cinara Cássia Brandão de Mattos; Antonio Helio Oliani; Denise Cristina Mós Vaz-Oliani; Luiz Carlos de Mattos
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Adenosine deaminase polymorphism affects sleep EEG spectral power in a large epidemiological sample.

Authors:  Diego Robles Mazzotti; Camila Guindalini; Altay Alves Lino de Souza; João Ricardo Sato; Rogério Santos-Silva; Lia Rita Azeredo Bittencourt; Sergio Tufik
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  Evaluation of the adenosine deaminase (ADA) G22A gene polymorphism with recurrent spontaneous abortion among Egyptian patients.

Authors:  Hanan Mohamed Farhan; Khadiga Abu-Gabal; Maha Katta; Raghda Ibrahim
Journal:  Cent Eur J Immunol       Date:  2017-10-30       Impact factor: 2.085

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.